Brolucizumab (Beovu▼): risk of intraocular inflammation and retinal vascular occlusion increased with short dosing intervals

2022-01-18T13:18:29+00:00

Maintenance doses of brolucizumab (after the first 3 doses) should not be given at intervals of less than 8 weeks apart.